Despite the combinations of chemotherapy with monoclonal antibodies have further
improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease …

Background Certain genomic features, such as del (11q), expression of unmutated
immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict …

The use of autologous haematopoietic stem cell transplantation (ASCT) has increased
considerably in lymphoid malignancies in the last decade, and it is now considered as the …

It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to
increase in an era where rituximab-containing chemotherapy reigns for almost two decades …

Hematopoietic stem cell transplantation (HSCT) is used with increasing frequency in Europe
with 40 000 transplants reported in 2014. Transplant-related mortality remains high in …

Introduction Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),
characterized by its monoclonal lymphoproliferative nature, is an indolent but incurable …

Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from
salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent …

To improve the prognosis of patients with poor-risk chronic lymphocytic leukemia (CLL),
efforts to develop effective treatment strategies have focused on autologous and allogeneic …

Although there have been recent advances with targeted therapies in chronic lymphocytic
leukemia (CLL), chemoimmunotherapy remains the treatment of choice; however, this …

Today's treatment options for indolent lymphoma and chronic lymphocytic leukemia (CLL)
range from watch & wait, immunochemotherapy up to allogeneic transplantation. We …